On the GoozNews blog, Merrill Goozner dissects the current decision by the US Center for Medicare and Medicaid Services (CMS) to make more lenient the criteria it uses to decide which off-label anti-cancer drugs it will pay for. Now any drug rated favorably in at least one of several drug compendia will be approved. Yet it turns out that intricate, but important conflicts of interest might affect how drugs get positive reviews in some of the compendia. It does seem that almost every piece of our fiendishly complex health care system is affected by conflicts of interest. To put the most positive interpretation on it, most US government agencies that deal with health care seem to have operated up to now in ignorant bliss when it comes to these conflicts.
[Source : Health Care Renewal]
Please take the time to visit original contents source to find out more about topic you are interested.
